Biologics License Application is Accepted by FDA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biologics License Application is Accepted by FDA for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC) Avelumab has previously received FDA Breakthrough Therapy and Fast [..]